Tag: technology

Posts with tag: technology

Latest Posts

Denmark Ramps Up Inspections of Ships Carrying Russian Oil

Denmark to Ramp Up Inspections of Ships Carrying Russian Oil Amid Maritime Safety Concerns

Tech Stocks Resume 'Buy the Dip' Mentality, Fueled by Leverage

Tech investors are sticking to the "buy the dip" strategy despite two market shocks in less than three weeks of Trump's second term. Leveraged ETFs and retail traders are pouring money into the market, showing the resilience of this mentality.

Wall Street Stays Bullish Amidst Noise: Strong Earnings, Economic Data Offset Trade War Concerns

Despite recent market volatility driven by trade war concerns, the stock market exhibits resilience, with analysts citing strong earnings growth, healthy economic data, and optimism about the future outlook.

Disney Q1 Earnings Beat Estimates, Streaming Segment Swings to Profit

Disney reports Q1 earnings beat, hitting profitability in streaming despite subscriber decline and hurricane impact.

Wall Street's Top Research Calls: AMD, Spotify Downgraded

Top analysts downgrade AMD and Spotify; Robinhood, CoStar, and Opera initiated

Tech Slumps on Concerns Over AI Investment Returns

Stocks dropped as underwhelming results from Alphabet Inc. and Advanced Micro Devices Inc. revived concerns about when the tech industry's AI spending will pay off.

The 'Buy the Dip' Playbook Is Alive and Kicking in Tech

Tech stocks rebound after two market shocks, with investors embracing the "buy the dip" strategy. Despite volatility, optimism remains strong, with leveraged ETFs seeing significant inflows.

Uber's Q1 Outlook Disappoints: Currency Headwinds, Winter Weather Impact Bookings

Uber reports a muted outlook for Q1 bookings due to currency headwinds and extreme weather, as legal expenses rise and the company expands into new revenue streams.

Novo Nordisk Beats Q4 Estimates, Stock Jumps Over 3%

Novo Nordisk beats earnings estimates, driven by blockbuster weight loss drugs that account for 60% of revenue. The company anticipates slower growth in 2025 but remains optimistic due to positive early trial data for next-generation drugs. Potential headwinds include generic competition and Medicare drug pricing negotiations.

Azenta's (AZTA) Q4 Revenue Tops Estimates: Buy or Sell?

Azenta's (NASDAQ: AZTA) Q4 revenue of $147.5 million surpassed expectations but declined 4.4% YoY, while non-GAAP EPS of $0.05 met estimates. Explore our full research report to assess Azenta's quality and valuation as an investment opportunity.